A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Andexxa is a modified form of the human Factor Xa molecule, an enzyme that helps blood clot. Anticoagulant reversal for life-threatening bleeds Mechanism of Action Andexxa is a recombinant protein specifically designed to bind to Factor Xa inhibitors and rapidly reverse their anticoagulant effect.FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019 Mechanism of Action Andexanet alfa acts as a decoy and sequesters rivaroxaban or apixaban, inhibiting them from binding to natural factor Xa.Inhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI), increasing tissue factor-initiated thrombin generation.Binds and sequesters factor Xa inhibitors.reversal agent with a distinct mechanism of action within the coagulation cascade. Among most patients, this serves to improve platelet function in a nonspecific fashion. ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo) is a. on Willebrand factor binds the GPIIb-IIIa receptor on platelets, causing platelet aggregation. Dosage Forms: solution reconstituted, 100 mg per vialĪdult Dosing Determined by last dose, type of factor Xa inhibitor, and dose of inhibitorĤ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 4 mg/minute for up to 120 minutesĨ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 8 mg/minute for up to 120 minutes DDAVP increases the release of von Willebrand Factor and factor VIII from the endothelium.Type: factor Xa inhibitor reversal, antidote Intravenous andexanet alfa coagulation factor Xa (recombinant), inactivated-zhzo Andexxa ® is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors.Another observed procoagulant effect of the ANDEXXA protein is its ability to bind to, and inhibit the activity of, Tissue Factor Pathway Inhibitor (TFPI). 2.1 Determined by last dose, type of factor Xa inhibitor, and dose of inhibitor Coagulation factor Xa (recombinant), inactivated-zhzo exerts its procoagulant effect by binding and sequestering the FXa inhibitors, rivaroxaban and apixaban.
0 Comments
Leave a Reply. |